Why the study?
Does nateglinide monotherapy improve HbA1c in elderly patients with type 2 diabetes and renal impairment?
Population
3,702 patients with type 2 diabetes from pooled data of 13 trials. Subgroup of interest: patients over age…
Comparison
Nateglinide monotherapy vs Placebo
Design
Meta-analysis, 12 randomized trials and 1 open trial, double blind
Authors
Loading...
Supports nateglinide monotherapy in elderly type 2 diabetes with renal impairment; extends meta-analytic evidence to this high-risk subgroup.
Does nateglinide monotherapy improve HbA1c in elderly patients with type 2 diabetes and renal impairment?
Nateglinide monotherapy is effective and well-tolerated for glycemic control in elderly patients with type 2 diabetes, including those with renal impairment.
Prato et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: